2021
QOLP-03. OBSERVATIONS OF COMPLEMENTARY CANNABIS THERAPY IN MALIGNANT GLIOMA PATIENTS
Blondin N. QOLP-03. OBSERVATIONS OF COMPLEMENTARY CANNABIS THERAPY IN MALIGNANT GLIOMA PATIENTS. Neuro-Oncology 2021, 23: vi183-vi183. PMCID: PMC8598802, DOI: 10.1093/neuonc/noab196.724.Peer-Reviewed Original ResearchMalignant glioma patientsMedical marijuana programMalignant gliomasInactive patientsCannabis therapyActive patientsComplementary therapiesGlioma patientsOil supplementsCannabis productsMedian overall survivalSignificant palliative benefitSerious adverse eventsOverall survivalAdverse eventsDaily groupPalliative benefitCannabis treatmentPatientsPatient registration processOil groupTherapyGliomasMonthsSurvival
2017
PALL-07. COMPLEMENTARY CANNABIS THERAPY FOR MALIGNANT GLIOMA: INITIAL EXPERIENCE
Blondin N. PALL-07. COMPLEMENTARY CANNABIS THERAPY FOR MALIGNANT GLIOMA: INITIAL EXPERIENCE. Neuro-Oncology 2017, 19: vi169-vi169. PMCID: PMC5692009, DOI: 10.1093/neuonc/nox168.688.Peer-Reviewed Original ResearchMalignant glioma patientsCannabis treatmentGlioma patientsCannabis therapyInitial experienceTherapeutic useBeneficial palliative effectBrain tumor symptomsCertain medical conditionsLow usePalliative useStandard therapyTumor symptomsOral sprayTherapeutic roleMalignant gliomasPalliative effectMild fatigueAnaplastic astrocytomaMedical conditionsAstrocytoma casesGlioblastoma patientsPatientsSide effectsAnimal models